Barbados vs Bolivia: Share of the population living with HIV receiving antiretroviral therapy
Barbados
60.4%
in 2024
Bolivia
59.7%
in 2024
Barbados rank
111th
Bolivia rank
112th
Share of the population living with HIV receiving antiretroviral therapy over time
- Barbados
- Bolivia
How they compare
Barbados currently reports 60.4% against 59.7% in Bolivia, a difference of 0.7%.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Bolivia ahead.
Barbados ranks 111th and Bolivia ranks 112th of 149 countries.
Barbados has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Barbados | Bolivia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.1% | 0.0% | 0.1% | Barbados |
| 2000s | 18.8% | 1.6% | 17.1% | Barbados |
| 2010s | 47.4% | 21.4% | 25.9% | Barbados |
| 2020s | 58.4% | 52.6% | 5.8% | Barbados |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Barbados or Bolivia?
- Barbados, at 60.4% against 59.7% in Bolivia as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Barbados and Bolivia?
- 0.7%, with Barbados ahead.
- How many years of comparable data are there for Barbados and Bolivia?
- 35 years are reported by both, from 1990 to 2024.
- How do Barbados and Bolivia rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Barbados ranks 111th and Bolivia ranks 112th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.